Cellulitis

Reading File

Finding Sources

Searching Images

cellulitis skin infection erythema swelling lower leg

This clinical photograph displays the lower extremity of a patient, demonstrating classic physical examination findings of cellulitis. The skin exhibits diffuse erythema and swelling extending across the anterior and lateral aspects of the leg. The texture is notably compromised, showing signs of desquamation (peeling), xerosis (dryness), and lichenification, particularly in the mid-to-lower portion. Multiple discrete skin lesions are visible, including areas of darker, crusted scabbing and potential ulceration that may serve as a portal of entry for infection. Small petechiae or ecchymotic spots are scattered within the erythematous region. The presentation is highly characteristic of an acute bacterial skin and soft tissue infection (SSTI), emphasizing the visual transition from healthy proximal skin to distal inflamed, edematous, and scaling tissue. This image is an educational resource for identifying inflammatory dermatological conditions and assessing secondary skin changes associated with chronic or severe cellulitis.

This clinical photograph shows a posterior view of a patient's lower legs, providing a side-by-side comparison between a healthy limb and a symptomatic one. The left lower leg (right side of the image) exhibits classic clinical signs of cellulitis, characterized by significant unilateral edema and diffuse erythema. The affected skin shows a spectrum of inflammatory discoloration, ranging from bright red to deep purplish hues, particularly over the calf region. The skin texture appears tense and glossy due to underlying swelling. A thin, vertical line of serous fluid exudate is visible on the posterior-lateral aspect of the left calf. In contrast, the right lower leg (left side of the image) appears normal with healthy skin tone and no evidence of swelling. This visual demonstrates the acute presentation of a soft tissue infection, useful for teaching the differential diagnosis of unilateral leg swelling and redness, which may include cellulitis, deep vein thrombosis (DVT), or localized vasculitis.

A sequence of three clinical photographs illustrating the progression of cellulitis on the lower leg, categorized by clinical severity. The 'Mild' stage (left) shows a localized, erythematous patch with poorly defined borders and scattered red papules. The 'Moderate' stage (center) demonstrates expanding confluent erythema and edema covering a larger surface area; notably, ink markings are visible on the skin to monitor the spread of infection. The 'Severe' stage (right) depicts intense, deep red to violaceous erythema involving the majority of the limb, accompanied by significant inflammatory swelling, a shiny skin texture suggestive of severe edema, and focal areas of potential skin breakdown or desquamation. This comparison highlights key diagnostic features of skin and soft tissue infections (SSTIs), including changes in color intensity, surface area involvement, and signs of tissue tension associated with worsening bacterial infection.

Searching PubMed

cellulitis skin AND infection management

Reading File

Loading Image

I now have comprehensive information from multiple authoritative textbooks. Let me compile the full response.

Cellulitis

Cellulitis is an acute bacterial infection of the skin and subcutaneous tissue, characterized by spreading erythema, warmth, edema, and tenderness. It is one of the most common skin infections seen in clinical practice, with a misdiagnosis rate as high as 30% in emergency settings.

Fig. 14.17 - Severe cellulitis of the lower leg showing intense erythema, edema, vesicle formation, and skin breakdown. (Andrews' Diseases of the Skin)

Definition & Pathophysiology

Cellulitis is a suppurative inflammation involving the subcutaneous tissue. It may be:

Nonpurulent - most common form; typically caused by beta-hemolytic streptococci (Group A Streptococcus accounts for ~75% of cases)
Purulent - drains freely; primarily caused by Staphylococcus aureus, including CA-MRSA

The inflammation involves increased local blood flow, edema, and recruitment of neutrophils. When localized edema becomes severe, epidermal layers can separate, leading to vesicles or bullae. Streaks of lymphangitis extending proximally are commonly seen, especially with streptococcal and Pasteurella multocida infections (bite wounds).

Andrews' Diseases of the Skin, p. 14.17
Rosen's Emergency Medicine, p. 2741

Etiology by Clinical Setting

Setting	Common Pathogens
Typical nonpurulent cellulitis	Streptococcus pyogenes (Group A), other beta-hemolytic streptococci
Purulent cellulitis / abscesses	S. aureus (CA-MRSA in most US cases)
Diabetic foot	S. aureus, streptococci (acute); polymicrobial with gram-negatives and anaerobes (chronic)
Cat bites	Pasteurella multocida
Human bites	Polymicrobial (Eikenella, Fusobacterium, Group A Streptococcus, S. aureus)
Seawater exposure	Vibrio vulnificus (especially in liver disease), Erysipelothrix rhusiopathiae
Freshwater exposure	Aeromonas spp.

Rosen's Emergency Medicine, p. 2741

Risk Factors

Disruption of the skin barrier: wounds, tinea pedis, dermatophyte infections
Venous insufficiency and stasis
Lymphedema (impaired lymphatic drainage)
Obesity
Diabetes mellitus
Immunocompromised states (HIV, malignancy, immunosuppressive drugs)
Prior saphenous vein harvesting, lymphadenectomy, or radiation
Alcoholism
Goldman-Cecil Medicine, Chapter 408
Andrews' Diseases of the Skin

Clinical Features

Symptoms: fever, chills, malaise, pain/tenderness at the site

Signs:

Erythema - rapidly spreading, poorly defined and irregular borders
Warmth and edema - the affected skin may pit on pressure
Vesicles or bullae - from severe localized edema
Lymphangitis - streaks extending proximally toward regional lymph nodes
Lymphadenopathy (regional)

Erysipelas is a distinct superficial form where the border is well-demarcated, raised, and palpable - most often caused by S. pyogenes.

Key clinical pearl: Cellulitis is rarely bilateral. Bilateral lower leg redness should strongly prompt consideration of other diagnoses (e.g., venous stasis dermatitis).

Rosen's Emergency Medicine, p. 2740-2741

Differential Diagnosis ("Pseudocellulitis")

The misdiagnosis rate can be as high as 30%. Key mimics:

Mimic	Distinguishing Features
Venous stasis dermatitis	Usually bilateral, centered over medial malleoli, no fever, no pain, often improves with elevation
Deep vein thrombosis (DVT)	Unilateral leg swelling, confirmed on Doppler ultrasound
Contact dermatitis	Pruritic rather than painful, no systemic signs
Erythema migrans (Lyme)	Target/bullseye appearance, >5 cm, central clearing, tick exposure history
Eosinophilic cellulitis	Exuberant insect bite reaction; eosinophilia rather than neutrophilia
Gout	Acute joint involvement, hyperuricemia, responds to NSAIDs
Fixed drug eruption	Drug exposure history
Necrotizing fasciitis	Pain out of proportion, rapid progression, bullae with dark fluid, systemic toxicity - surgical emergency

The ALT-70 score (Asymmetry, Leukocytosis, Tachycardia, age ≥70) has been proposed to help differentiate cellulitis from pseudocellulitis, though it requires further validation.

Rosen's Emergency Medicine, p. 2741
Andrews' Diseases of the Skin

Diagnosis

Cellulitis is primarily a clinical diagnosis.

Blood cultures: Not indicated in uncomplicated cases. Recommended for immunocompromised patients or systemic infection
Wound cultures: Needle aspiration, superficial swabs, and skin biopsy are low-yield in nonpurulent cellulitis and not routinely recommended. Useful in: purulent cellulitis, immunocompromised hosts, bite wounds, immersion injuries
Lab work (CBC, CRP, ESR): Not routinely needed but may help assess severity and guide hospitalization decisions
Bedside ultrasound: High-frequency linear probe helps differentiate cellulitis (hyperechoic/cobblestoning) from abscess (hypoechoic with posterior acoustic enhancement)
CT/MRI: Consider if necrotizing fasciitis is suspected
Rosen's Emergency Medicine, p. 2741-2742

Management

Outpatient (mild, non-toxic, immunocompetent)

Drug	Dose	Duration
Cephalexin (first-line)	500 mg QID orally	5-10 days
Dicloxacillin	500 mg QID orally	5-10 days
Clindamycin	300-450 mg QID orally	10 days
TMP-SMX	160/800 mg BID orally	10 days
Penicillin VK (streptococcal)	500 mg QID orally	10 days

If MRSA is strongly suspected (prior MRSA, failed beta-lactam, purulent infection), use clindamycin or TMP-SMX.

Inpatient / Severe

Criteria for hospitalization: systemic symptoms (fever), immunosuppression, diabetic foot infections, infected lymphedema, large or multifocal cellulitis, or failure of outpatient antibiotics.

IV nafcillin or oxacillin for MSSA
IV vancomycin (15-20 mg/kg BID) for MRSA or when pathogen unclear
Vancomycin + imipenem (or piperacillin-tazobactam) for severe/polymicrobial cases
If Group A Strep confirmed: IV Penicillin G (4 million units q4h) + IV Clindamycin (600-900 mg q8h) for 10-14 days

Adjunctive Measures

Limb elevation to reduce edema
Mark the borders of erythema with a skin marker to monitor progression
Compression therapy in lymphedema to reduce recurrence risk
Treat underlying risk factors (tinea pedis, venous insufficiency)
Goldman-Cecil Medicine
Andrews' Diseases of the Skin
Rosen's Emergency Medicine, p. 2742

Complications

Lymphangitis and regional lymphadenopathy
Bacteremia and sepsis
Necrotizing fasciitis - the most feared complication; requires emergent surgical debridement (mortality 30-60%, up to 70-85% when diagnosis delayed)
Metastatic abscesses
Gangrene
Chronic lymphedema / elephantiasis nostras verrucosa (from recurrent episodes)

Complications are unusual in immunocompetent adults but occur more often in children and immunocompromised adults. Most cases in immunocompetent adults improve within 4-6 days of treatment.

Recurrent Cellulitis - Prevention

Predisposing factors for recurrence: alcoholism, diabetes, immunodeficiency, tinea pedis, venous stasis, lymphedema, prior knee prosthesis, saphenous phlebectomy, lymphadenectomy, or irradiation.

Secondary prophylaxis: Penicillin 250 mg orally BID is effective for preventing recurrent cellulitis in patients with chronic lymphedema and 3 or more episodes per year. A 2026 systematic review (Sierla et al., PMID 41275489) and a 2025 review on non-pharmacological prevention (Jacka et al., PMID 40530782) both highlight that managing the underlying predisposing condition (lymphedema, tinea pedis) is central to reducing recurrence.

Recent Evidence

A 2024 meta-analysis on diagnostic stewardship (Lin et al., PMID 39614879) found that dermatology consultation significantly reduces cellulitis misdiagnosis and inappropriate antibiotic use. Given the high pseudocellulitis rate, early specialist input is worthwhile in uncertain cases.

Clinical Image Gallery

Cellulitis posterior lower legs - unilateral erythema and edema

Posterior view showing unilateral erythema and edema of the left lower leg - a classic presentation of cellulitis compared to the normal right leg.

Cellulitis severity progression - mild, moderate, severe stages

Sources: Andrews' Diseases of the Skin (Clinical Dermatology) | Rosen's Emergency Medicine | Goldman-Cecil Medicine | Textbook of Family Medicine 9e

Treatment

Finding Sources

Searching PubMed

cellulitis treatment antibiotics

Reading File

Reading Article

PMID: 39240378

Reading File

I now have rich, multi-source treatment content. Let me compile the comprehensive treatment-focused answer.

Cellulitis: Treatment

Treatment is guided by two key axes: purulent vs. nonpurulent infection, and severity (mild / moderate / severe).

General Measures (All Cases)

Elevate the affected limb - reduces edema and promotes drainage
Mark the border of erythema with a skin marker at presentation to monitor spread
Incision and drainage (I&D) if an abscess component is identified
Treat predisposing conditions: tinea pedis, venous insufficiency, lymphedema, skin dryness/cracking (topical emollients)
Optimize comorbidities: glycemic control in diabetes, compression therapy in lymphedema
Tintinalli's Emergency Medicine, p. 3890
Fischer's Mastery of Surgery 8e, p. 7912

Classification of Severity

Class	Features
Mild	No systemic symptoms; able to take oral medications
Moderate	Systemic symptoms (fever, tachycardia) but not septic; may need IV then step-down
Severe	Sepsis, rapid spread, immunocompromised, failed oral therapy, necrotizing features

A. Nonpurulent Cellulitis (Most Common)

The dominant pathogens are beta-hemolytic streptococci (Group A, B, C, G). MRSA is not a common cause of nonpurulent cellulitis.

Mild - Outpatient (Oral)

Drug	Dose	Duration
Cephalexin (first-line)	500 mg QID	5-10 days
Dicloxacillin	500 mg QID	5-10 days
Penicillin VK (confirmed streptococcal)	500 mg QID	10 days
Amoxicillin	500 mg TID	5-10 days
Clindamycin	300-450 mg QID	10 days

For uncomplicated cases, 5 days of cephalexin is often sufficient and as effective as longer courses. Adding TMP-SMX (dual MRSA/strep coverage) to cephalexin does not reduce treatment failure in uncomplicated nonpurulent cellulitis.

Moderate to Severe - Inpatient (IV)

Drug	Dose
Cefazolin (first-line IV)	1-2 g q8h
Nafcillin / Oxacillin	1-2 g q4-6h
Penicillin G (confirmed streptococcal)	2-4 million units q4-6h
Clindamycin (penicillin allergy)	600-900 mg q8h IV
Vancomycin (MRSA coverage needed, or severe)	15-20 mg/kg q8-12h IV

Step down to oral therapy once systemic symptoms resolve (usually 48-72 h).

Goldman-Cecil Medicine
Tintinalli's Emergency Medicine
Andrews' Diseases of the Skin

B. Purulent Cellulitis / MRSA-Suspected

CA-MRSA is the leading cause of purulent skin and soft tissue infections.

Mild - Outpatient (Oral)

Drug	Dose	Duration
TMP-SMX (first-line MRSA)	160/800 mg (1 DS tab) BID	5-10 days
Doxycycline	100 mg BID	5-10 days
Clindamycin (check D-zone test)	300-450 mg QID	10 days

Moderate to Severe - Inpatient (IV)

Drug	Dose
Vancomycin	15-20 mg/kg q8-12h
Daptomycin	4-6 mg/kg/day
Linezolid	600 mg q12h IV/PO
Tedizolid	200 mg daily

Rosen's Emergency Medicine
Fischer's Mastery of Surgery 8e

C. Special Situations

Penicillin Allergy

Non-IgE-mediated: first-generation cephalosporin is safe
IgE-mediated (anaphylaxis): use clindamycin, linezolid, or vancomycin

Diabetic Foot Infection

Acute: covers Staph/Strep - cephalexin or amoxicillin-clavulanate (oral); piperacillin-tazobactam or carbapenem (IV) for severe/chronic
Chronic/polymicrobial: broad-spectrum coverage including gram-negatives and anaerobes
Always add MRSA coverage (vancomycin) in severe or previously treated cases
Wound care, debridement, and revascularization as needed

Immunocompromised Patients

Lower threshold for hospitalization and IV therapy
Vancomycin + anti-gram-negative coverage (e.g., vancomycin + piperacillin-tazobactam or carbapenem)
Blood and wound cultures are indicated

Water/Environmental Exposure

Seawater (Vibrio vulnificus): doxycycline + ceftriaxone (especially in liver disease - high mortality risk)
Freshwater (Aeromonas): ciprofloxacin or TMP-SMX
Fish tank / aquarium (Mycobacterium marinum): clarithromycin or minocycline + rifampicin

Bite Wounds

Cat bites (Pasteurella multocida): amoxicillin-clavulanate - presumptive treatment appropriate given high infection rate
Dog bites: amoxicillin-clavulanate if prophylaxis indicated (hand, face, immunocompromised)
Human bites: amoxicillin-clavulanate or ampicillin-sulbactam (polymicrobial including Eikenella)

D. Indications for Hospitalization

Admit if any of the following are present:

Systemic toxicity (fever, tachycardia, hypotension)
Failure of 48-72 h of oral antibiotics
Immunosuppression (HIV, chemotherapy, steroids, transplant)
Diabetic foot infection
Infected lymphedema
Large or rapidly spreading cellulitis
Cellulitis overlying a joint, vascular graft, or prosthetic implant
Toxic shock syndrome features
Suspected necrotizing fasciitis (surgical emergency)
Rosen's Emergency Medicine, p. 2742
Fischer's Mastery of Surgery 8e, p. 7912

E. Duration of Therapy

Scenario	Duration
Uncomplicated mild cellulitis	5-6 days
Moderate cellulitis	10 days
Severe / immunocompromised	Up to 14 days
Streptococcal cellulitis (confirmed)	10-14 days

Hospitalized patients benefit from daily digital photographs of the involved area to objectively document response to treatment.

F. Recurrence Prevention (Secondary Prophylaxis)

Indicated when the patient has chronic lymphedema + 3 or more episodes/year:

Drug	Dose
Penicillin V	250 mg BID orally (long-term)
Erythromycin	250-500 mg daily (penicillin allergy)

Compression therapy to manage lymphedema is equally important for reducing recurrence. A 2026 systematic review (Sierla et al., PMID 41275489) confirmed that management of underlying predisposing conditions is the cornerstone of secondary prevention.

G. Necrotizing Fasciitis - When to Suspect & Escalate

Never miss this. Red flags warranting urgent surgical consultation:

Pain out of proportion to exam findings
Rapid progression despite antibiotics
Bullae with dark/bloody fluid
Skin necrosis or crepitus
Systemic shock

Management:

Immediate surgical exploration and aggressive debridement
Empiric broad-spectrum IV: vancomycin + piperacillin-tazobactam (or carbapenem + clindamycin)
Once Group A Strep confirmed: IV Penicillin G (4 million units q4h) + IV Clindamycin (600-900 mg q8h) for 10-14 days
Mortality: 30-60% even with appropriate treatment; up to 70-85% when diagnosis is delayed

Recent Evidence

A 2024 network meta-analysis (Shu et al., PMID 39240378) analyzing 10 RCTs with 1,936 patients found:

No significant differences in cure rates among the major antibiotics studied for cellulitis (cephalexin, clindamycin, TMP-SMX, ceftriaxone, flucloxacillin, penicillin)
Cefaclor had the most favorable curative profile for cellulitis
Ceftriaxone had the fewest GI side effects
This supports current guidelines that multiple agents are acceptable first-line options

Sources: Tintinalli's Emergency Medicine | Rosen's Emergency Medicine | Andrews' Diseases of the Skin | Goldman-Cecil Medicine | Fischer's Mastery of Surgery 8e

Inj

Finding Sources

Reading File

I have all the key data. I can now see Table 126.2 is the oral antibiotic table. From the previous reads I already have all the IV dosing. Let me compile the complete injectable antibiotic guide.

Cellulitis: Injectable (IV/IM) Antibiotics

Injectable antibiotics are used when oral therapy is not appropriate - due to severity, systemic toxicity, failed oral treatment, immunosuppression, or the need for rapid drug levels. The choice depends on purulent vs. nonpurulent infection and MRSA risk.

When to Use Injectables

Indication	Route
Systemic symptoms (fever, tachycardia, hypotension)	IV
Failed 48-72 h of oral antibiotics	IV
Immunocompromised (HIV, steroids, transplant, chemotherapy)	IV
Diabetic foot infection (moderate-severe)	IV
Infected lymphedema	IV
Large, rapidly spreading, or multifocal cellulitis	IV
Sepsis / suspected necrotizing fasciitis	IV (urgent)
Unable to tolerate oral medications	IV or IM

1. Nonpurulent Cellulitis (Streptococcal, No MRSA Risk)

First-Line IV

Drug	Adult Dose	Frequency	Notes
Cefazolin	1-2 g	q8h IV	First-line IV agent; well tolerated
Nafcillin	1-2 g	q4-6h IV	Anti-staphylococcal penicillin; MSSA coverage
Oxacillin	1-2 g	q4-6h IV	Equivalent to nafcillin
Penicillin G	2-4 million units	q4-6h IV	When Group A Strep confirmed
Ampicillin-sulbactam	1.5-3 g	q6h IV	Adds anaerobic/gram-negative coverage

Penicillin-Allergic (Non-anaphylactic)

Drug	Adult Dose	Frequency
Cefazolin	1-2 g	q8h IV (safe if non-IgE allergy)
Clindamycin	600-900 mg	q8h IV

Penicillin-Allergic (IgE-mediated / Anaphylaxis)

Drug	Adult Dose	Frequency
Clindamycin	600-900 mg	q8h IV
Vancomycin	15-20 mg/kg	q8-12h IV
Linezolid	600 mg	q12h IV/PO

2. Purulent Cellulitis / MRSA Suspected or Confirmed

Drug	Adult Dose	Frequency	Notes
Vancomycin	15-20 mg/kg	q8-12h IV	Standard MRSA agent; monitor trough levels or AUC
Daptomycin	4-6 mg/kg	Once daily IV	Alternative to vancomycin; cannot use in pneumonia
Linezolid	600 mg	q12h IV or PO	IV bioequivalent to oral; useful step-down
Tedizolid	200 mg	Once daily IV	Newer oxazolidinone; good MRSA coverage

Vancomycin is the recommended parenteral agent for MRSA in cellulitis.

3. Severe / Sepsis / Unknown Source

Broad-spectrum empiric coverage while awaiting cultures:

Regimen	Indication
Vancomycin + Piperacillin-tazobactam	Sepsis with suspected skin source; covers MRSA + gram-negatives + anaerobes
Vancomycin + Carbapenem (imipenem/meropenem)	Severe immunocompromised; MDR organisms possible
Vancomycin + Cefepime	Neutropenic or high gram-negative risk

Standard dosing for the combination agents:

Drug	Dose	Frequency
Vancomycin	15-20 mg/kg	q8-12h
Piperacillin-tazobactam	3.375 g (or 4.5 g)	q6h (or q8h extended infusion)
Imipenem	500 mg	q6h
Meropenem	1 g	q8h
Cefepime	1-2 g	q8-12h

4. Necrotizing Fasciitis (Surgical Emergency)

Requires immediate surgical debridement + broad-spectrum IV antibiotics:

Empiric (polymicrobial coverage):

Drug	Dose	Frequency
Vancomycin	15-20 mg/kg	q8-12h IV
+ Piperacillin-tazobactam	3.375-4.5 g	q6-8h IV
OR + Carbapenem	500 mg (imipenem)	q6h IV
+ Clindamycin	600-900 mg	q8h IV (anti-toxin effect)

Once Group A Strep confirmed (narrow down to):

Drug	Dose	Frequency	Duration
Penicillin G	4 million units	q4h IV	10-14 days
+ Clindamycin	600-900 mg	q8h IV	10-14 days

Clindamycin is kept even with penicillin because it inhibits toxin production by Group A Strep via ribosomal (50S) blockade - this is the rationale for dual therapy.

5. Novel Long-Acting Lipoglycopeptides (Single/Weekly Dose)

These agents cover all major cellulitis pathogens including MRSA, with extremely long half-lives:

Drug	Dose	Regimen	Notes
Oritavancin (Orbactiv)	1200 mg	Single IV infusion (3 h)	Entire course in one dose; useful to avoid admission
Dalbavancin (Dalvance)	1500 mg	Single IV infusion OR 1000 mg then 500 mg on Day 8	Once-weekly regimen

These are particularly useful for patients who need IV-level treatment but lack an absolute indication for hospitalization (e.g., no sepsis, no surgical emergency, concerns about oral compliance).

Rosen's Emergency Medicine, p. 2742

6. Special Scenarios - Injectable Choice

Scenario	Preferred IV Agent
MSSA confirmed	Nafcillin / Oxacillin / Cefazolin
MRSA confirmed	Vancomycin (first-line); Daptomycin or Linezolid (alternatives)
Seawater exposure (Vibrio)	Doxycycline 100 mg IV q12h + Ceftriaxone 1-2 g IV once daily
Freshwater (Aeromonas)	Ciprofloxacin 400 mg IV q12h
Necrotizing (polymicrobial)	Vancomycin + Pip-tazo + Clindamycin
Penicillin allergy + MSSA	Clindamycin or Vancomycin IV
Diabetic foot (severe)	Vancomycin + Pip-tazo or Carbapenem
Neutropenic	Vancomycin + antipseudomonal agent

Step-Down to Oral

Once the patient is afebrile, erythema is improving/stable, and they can tolerate oral medications (usually 48-72 h after starting IV):

IV Drug Used	Step Down To
Cefazolin	Cephalexin 500 mg QID
Nafcillin / Oxacillin	Dicloxacillin 500 mg QID
Vancomycin (MRSA)	TMP-SMX DS 1 tab BID or Doxycycline 100 mg BID
Clindamycin IV	Clindamycin 300-450 mg QID orally
Linezolid IV	Linezolid 600 mg q12h orally (bioequivalent)

Total duration: 5-6 days (uncomplicated) to 10-14 days (severe or immunocompromised), counting both IV and oral phases together.

Sources: Rosen's Emergency Medicine (Table 126.2, 127.3) | Goldman-Cecil Medicine | Fischer's Mastery of Surgery 8e | Andrews' Diseases of the Skin

This is a shared conversation. Sign in to Orris to start your own chat.